Center for Community Outreach and Policy, Department of Ophthalmology, Stein & Doheny Eye Institutes, David Geffen School of Medicine at UCLA, Los Angeles, California.
Icahn School of Medicine at Mount Sinai, New York, New York.
Ophthalmol Glaucoma. 2024 Nov-Dec;7(6):563-571. doi: 10.1016/j.ogla.2024.07.008. Epub 2024 Jul 31.
To investigate associations between statin use and glaucoma in the 2017 to 2022 All of Us (AoU) Research Program.
Cross-sectional, population-based.
79 742 adult participants aged ≥40 years with hyperlipidemia and with electronic health record (EHR) data in the AoU database.
Hyperlipidemia, glaucoma status, and statin use were defined by diagnoses and medication information in EHR data collected by AoU. Logistic regression analysis was performed to evaluate the association between statin use and glaucoma likelihood. Logistic regression modeling was used to examine associations between glaucoma and all covariates included in adjusted analysis. Serum low-density lipoprotein cholesterol (LDL-C) was used to assess hyperlipidemia severity. Analyses stratified by LDL-C level and age were performed.
Any glaucoma as defined by International Classification of Diseases codes found in EHR data.
Of 79 742 individuals with hyperlipidemia in AoU, there were 6365 (8.0%) statin users. Statin use was associated with increased glaucoma prevalence when compared with statin nonuse (adjusted odds ratio [aOR]: 1.13, 95% confidence interval [CI]: 1.01-1.26). Higher serum levels of LDL-C were associated with increased odds of glaucoma (aOR: 1.003, 95% CI: 1.003, 1.004). Statin users had significantly higher LDL-C levels compared to nonusers (144.9 mg/dL versus 136.3 mg/dL, P value < 0.001). Analysis stratified by LDL-C identified positive associations between statin use and prevalence of glaucoma among those with optimal (aOR = 1.39, 95% CI = 1.05-1.82) and high (aOR = 1.37, 95% CI = 1.09-1.70) LDL-C levels. Age-stratified analysis showed a positive association between statin use and prevalence of glaucoma in individuals aged 60 to 69 years (aOR = 1.28, 95% CI = 1.05-1.56).
Statin use was associated with increased glaucoma likelihood in the overall adult AoU population with hyperlipidemia, in individuals with optimal or high LDL-C levels, and in individuals 60 to 69 years old. Findings suggest that statin use may be an independent risk factor for glaucoma, which may furthermore be affected by one's lipid profile and age.
Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
在 2017 至 2022 年全美健康与营养调查（All of Us，AoU）研究计划中，调查他汀类药物使用与青光眼之间的关联。
横断面，基于人群。
79742 名年龄≥40 岁、患有高脂血症且在 AoU 数据库中有电子健康记录（EHR）数据的成年参与者。
高脂血症、青光眼状态和他汀类药物的使用情况通过 AoU 收集的 EHR 数据中的诊断和药物信息来定义。使用逻辑回归分析评估他汀类药物使用与青光眼可能性之间的关联。使用逻辑回归模型检查青光眼与调整分析中包含的所有协变量之间的关联。血清低密度脂蛋白胆固醇（LDL-C）用于评估高脂血症的严重程度。进行了按 LDL-C 水平和年龄分层的分析。
EHR 数据中发现的任何由国际疾病分类代码定义的青光眼。
在 AoU 中患有高脂血症的 79742 名个体中，有 6365 名（8.0%）他汀类药物使用者。与他汀类药物非使用者相比，他汀类药物使用者的青光眼患病率更高（调整后的优势比[aOR]：1.13，95%置信区间[CI]：1.01-1.26）。较高的血清 LDL-C 水平与青光眼的发病几率增加相关（aOR：1.003，95%CI：1.003，1.004）。与非使用者相比，他汀类药物使用者的 LDL-C 水平显著升高（144.9mg/dL 比 136.3mg/dL，P 值<0.001）。按 LDL-C 分层的分析表明，在 LDL-C 水平理想（aOR=1.39，95%CI=1.05-1.82）和高（aOR=1.37，95%CI=1.09-1.70）的人群中，他汀类药物使用与青光眼的患病率之间存在正相关。按年龄分层的分析显示，在 60 至 69 岁的个体中，他汀类药物使用与青光眼的患病率之间存在正相关（aOR=1.28，95%CI=1.05-1.56）。
在患有高脂血症的总体 AoU 成年人群中、在 LDL-C 水平理想或高的个体中以及在 60 至 69 岁的个体中，他汀类药物使用与青光眼的可能性增加相关。这些发现表明，他汀类药物使用可能是青光眼的一个独立危险因素，并且可能进一步受到个体的血脂谱和年龄的影响。
在本文末尾的脚注和披露中可能找到专有或商业披露信息。
